A N Chirkov Selected Research

Ischemic Stroke

1/2022	[Nonimmunogenic staphylokinase in the treatment of acute ischemic stroke (FRIDA trial results)].
1/2022	[Intravenous thrombolytic therapy of ischemic stroke with the drug Revelisa in real clinical practice: results of the IVT-AIS-R study].
1/2021	[Intravenous thrombolytic therapy with Revelisa of ischemic stroke in real-world clinical practice: interim results of an open-label, prospective, multicenter, non-interventional study IVT-AIS-R].
1/2017	[Algorithms of the correction of fluid and electrolyte disorders in patients with severe ischemic stroke].
11/2016	PROGNOSTIC SIGNIFICANCE OF WATER AND ELECTROLYTE DISORDERS IN THE ACUTE PERIOD OF SEVERE ISCHEMIC STROKE.
1/2016	[Hypovolemic hyponatremia at the onset of severe ischemic stroke as a predictor of adverse outcome].

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

A N Chirkov Research Topics

Disease

6	Ischemic Stroke 01/2022 - 01/2016
2	Stroke (Strokes) 01/2021 - 01/2017
1	Body Weight (Weight, Body) 01/2022
1	Hyponatremia 01/2017
1	Hypernatremia 01/2017

Drug/Important Bio-Agent (IBA)

3	Tissue Plasminogen Activator (Alteplase)FDA Link 01/2022 - 01/2021
3	ElectrolytesIBA 01/2017 - 01/2016
1	Staphylococcus aureus auR protein (staphylokinase)IBA 01/2022
1	SodiumIBA 01/2017
1	Vasopressins (Vasopressin)IBA 01/2017

Therapy/Procedure

3	Thrombolytic Therapy 01/2022 - 01/2021
1	Therapeutics 01/2021
1	Contraindications 01/2021